ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma immunology genetics genomics

Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Avant-Garde Science
Mary Beth Aberlin | Jun 1, 2012 | 3 min read
Why naked mole-rats and experimental gene therapies remind me of groundbreaking artists.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
dual expresser t cell immunology type 1 diabetes
The Science News that Shaped 2019
Kerry Grens | Dec 20, 2019 | 6 min read
A T cell discovery, “hachimoji” DNA, a new species of human, and mounting fears of espionage rounded off the list this year.
New Approaches to Discovery Push Research at Big Biotech
James Kling | May 24, 1998 | 6 min read
The biotechnology industry is among the biggest employers of life science professionals, with 140,000 employees generating $17.4 billion of revenue in 1997, according to an industry report by Ernst & Young LLP of Palo Alto, Calif. Since the birth of biotechnology in the 1970s, many of the seminal companies--such as Biogen and Genentech-- have matured into profitable or near- profitable companies. As these companies arose, venture capitalists fell in love with start-up biotechs in the 1980s
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Immune to Failure
Karen Hopkin | Feb 1, 2013 | 9 min read
With dogged persistence and an unwillingness to entertain defeat, Bruce Beutler discovered a receptor that powers the innate immune response to infections—and earned his share of a Nobel Prize.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th

Run a Search

ADVERTISEMENT